Our Fund

Tiger Jade Capital is founded in 2019 with its headquarters in Hong Kong. It is a comprehensive healthcare fund covering new drugs, CRO, medical equipment, etc.

Tiger Jade Capital aspires to aggregate conscious capital to improve people’s well being and contribute to community with total dedication and integrity; and as a result, deliver optimal returns for our investors.

As a pledge, 5% of Tiger Jade Capital’s GP management fee profit and carry income will be donated to charities supporting underprivileged groups.

Senior Advisor of Investment Committee

Dr. Ye, Chairman, Tigermed Consulting Company

Dr. Xiaoping Ye is the founder, Chairman of Hangzhou Tigermed Consulting Co. Ltd.  With two decades of experience in medical and regulatory affairs, Dr. Ye worked at global pharmaceutical companies including Xi’an-Janssen, Bristol-Myers Squibb, and Shanghai Roche before founding Tigermed. He graduated from Nanjing Medical College before receiving his DPhil degree in Immunology from Oxford University and EMBA from the Guanghua School of Management, Peking University.

Dr.Ye has an incredible track record in healthcare investment: According to Touzhong Group listing, 4 out of the “China Top 10 Best Biotech Investments” in 2018 were led by Dr.Ye; In 2019, 3 of his investments have gone IPO by June; another 15 deals are in the process of waiting for IPO approval.

GP Team

Founding Partner:Jasper Jiang

10+ PE experience from 2008 working in the leading PE firm Capital Today that has led famous investments in, Three Squirrels, Yifeng Pharmacy and many more. Focused on consumer, retail and internet and helping the entrepreneurs to build No.1 brand in China.

Engaged or/and led deals such as leading herbal skincare brand Xiang Yi Ben Cao, Afiona beauty retail, City Beauty underwear retail, Befengtang restaurant chain,  Also Led investments such asYanLi cosmetics chain a1 food company,  thatgamecompany etc.

12 years in P&G China marketing in senior brand management role responsible for over RMB 2 Billion brand business.
Double bachelor degree in Biochemical Engineering and Economics from South China University of Technology EMBA degree from China Europe International Business School in 2011.

Founding Partner:  Stacey Ying Liu

10+ years cross-industry operational experience in marketing & brand management leading MNCs such as P&G, HP and Orange (France Telecom) across Greater China & Europe, Middle East & Africa markets.

VP for global marketing in France Telecom/Orange leading marketing planning & strategy across 8 major countries in Europe; Market manager in HP Printing and PC divisions for EMEA and P&G for China market. Managed annual budget over US$30MM.

5+ years working in consulting & building organization capability areas for pharmaceutical industryand beyond such as Pfizer, GSK, Novartis, Merck, Johnson & Johnson, Shell, HSBCetc via Brand-learning/Accenture Consulting.

Double bachelor degree in Biochemical Engineering and Economics from SCUT (South China University of Technology)

MBA degree from University of Cambridge, UK;  Value-Investing Executive Education from Columbia University.

Principal:  Emmanuel Hui

5+ years in private equity market. Emmanuel was the Founding CEO of Moogene Medi, a gene therapy company listed on the Korean Stock Exchange (322970.KS). After his exit, Emmanuel returned to Hong Kong and joined Sagamore Investments, a China-focused private equity firm where he oversaw healthcare and life science fund/company investments. Emmanuel is also on the Board of Tonisity China – an animal health feed additive product company.

Emmanuel is deeply engaged in building Hong Kong’s biomedical ecosystem. He is a Board Member of the Hospital Authority Central Institutional Review Board (Paediatrics), Member of the HKSTP Biomedical Technology Development Advisory Panel (2021-22), Advisory Board Member of the Hong Kong Life Science Society, Advisor to FoundersHK, and has sat on multiple TSSSU Panels.

Emmanuel graduated from Dartmouth College as a Senior Fellow in Chemistry.

Venture Partner:  Jack Wang

15+ experience in the finance industry across public and private market. Jack has been a Venture Partner since December 2023. Prior to being the Venture Partner, Jack was a Partner at Tiger Jade from January 2022 to December 2023. From June 2017 to January, 2022, Jack served as a Managing Director at CMB International Asset Management Limited (“CMBI”), where he led the firm’s effort in various notable investments including Tencent Music Entertainment Group, Xiaomi Corporation, and Grab Holdings Inc., etc and worked closely with the firm’s healthcare team and participated in project fund investing in leading healthcare companies in China, such as Burning Rock Biotech Limited and Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Prior to joining CMBI, Jack worked at CSOP Asset Management Limited from April 2012 to August 2016 with his last position being the Deputy Chief Marketing Officer, where he was instrumental in building the firm to become the largest RMB QFII player in the market. Jack also worked at Deutsche Securities Asia and Goldman Sachs (Asia) L.L.C. from November 2006 to March 2012.

Bachelor’s Degree in Economics from Tsinghua University.

Venture Partner:  Andrew Cowell

Highly experienced and successful global executive in Finance, Sales & General management; ex-General Manager of Coca-Cola, impressive track record in leadership and operational management.

Led £800 million+ turnover JV between Coke & Nestle in EMEA and achieved 50% growth in 2 years 10+ years experience in investment across industries in consumer goods, high-tech, health care etc. Business Degree from Leeds Metropolitan University